Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171056
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarroso Fernández, Emma-
dc.contributor.authorRodríguez-Rodríguez, Rosalia-
dc.contributor.authorZarei, Mohammad-
dc.contributor.authorPizarro Delgado, Javier-
dc.contributor.authorPlanavila Porta, Ana-
dc.contributor.authorPalomer Tarridas, Francesc Xavier-
dc.contributor.authorVillarroya i Gombau, Francesc-
dc.contributor.authorVázquez Carrera, Manuel-
dc.date.accessioned2020-10-06T08:20:15Z-
dc.date.available2020-10-06T08:20:15Z-
dc.date.issued2020-09-10-
dc.identifier.issn1478-811X-
dc.identifier.urihttp://hdl.handle.net/2445/171056-
dc.description.abstractBackground: Deficiency of mitochondrial sirtuin 3 (SIRT3), a NAD+ -dependent protein deacetylase that maintains redox status and lipid homeostasis, contributes to hepatic steatosis. In this study, we investigated additional mechanisms that might play a role in aggravating hepatic steatosis in Sirt3-deficient mice fed a high-fat diet (HFD). Methods: Studies were conducted in wild-type (WT) and Sirt3−/− mice fed a standard diet or a HFD and in SIRT3- knockdown human Huh-7 hepatoma cells. Results: Sirt3−/− mice fed a HFD presented exacerbated hepatic steatosis that was accompanied by decreased expression and DNA-binding activity of peroxisome proliferator-activated receptor (PPAR) α and of several of its target genes involved in fatty acid oxidation, compared to WT mice fed the HFD. Interestingly, Sirt3 deficiency in liver and its knockdown in Huh-7 cells resulted in upregulation of the nuclear levels of LIPIN1, a PPARα co-activator, and of the protein that controls its levels and localization, hypoxia-inducible factor 1α (HIF-1α). These changes were prevented by lipid exposure through a mechanism that might involve a decrease in succinate levels. Finally, Sirt3−/− mice fed the HFD showed increased levels of some proteins involved in lipid uptake, such as CD36 and the VLDL receptor. The upregulation in CD36 was confirmed in Huh-7 cells treated with a SIRT3 inhibitor or transfected with SIRT3 siRNA and incubated with palmitate, an effect that was prevented by the Nrf2 inhibitor ML385. Conclusion: These findings demonstrate new mechanisms by which Sirt3 deficiency contributes to hepatic steatosis-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12964-020-00640-8-
dc.relation.ispartofCell Communication and Signaling, 2020, vol. 18, num. 147-
dc.relation.urihttps://doi.org/10.1186/s12964-020-00640-8-
dc.rightscc-by (c) Barroso Fernández, Emma et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)-
dc.subject.classificationMalalties del fetge-
dc.subject.classificationLípids-
dc.subject.otherLiver diseases-
dc.subject.otherLipids-
dc.titleSIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec703469-
dc.date.updated2020-10-06T08:20:15Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32912335-
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
703469.pdf2.68 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons